Researchers looked at data from 80 patients with metastatic castration-resistant prostate cancer to see how they responded to a specific treatment called 161Tb-PSMA radioligand therapy. This analysis combined results from six different studies to get a clearer picture of the treatment's impact.
The findings showed that about 83.9% of patients experienced disease control. Additionally, more than half of the patients, specifically 50.2%, showed an objective response to the treatment. While many side effects were reported, only 18% of those events were considered high grade, suggesting the treatment has a manageable safety profile.
It is important to note that these results come from a small group of patients across only six studies. Because the data comes from a small sample and shows significant differences in how patients responded, more large-scale trials are needed. This finding suggests the therapy is a potential option for this type of cancer, but it is not yet a standard replacement for current treatments.
